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INSTRUCTIONS 
PHS policy requires that grantees submit a "terminal 
progress report" (final report) within 90 days after 
completion of the grant. 
Please complete this series of items as this final report. 
The report will be filed with your applications, reports 
and other grant business in NIMH's central files. It will 
be read by staff in research program areas, and may be 
read by other Institute staff concerned with program 
analysis, .communication, evaluation and planning. The 
report will be used for information about your research, 
i.e., to describe and summarize the information (proce-
dural as well as substantive) resulting from NIMH 
support, and to relate that information to mental health 
problems and 'research. Your report will often be used 
apart from your application; however, other documents, 
such as publications and applications, will be available 
from the project file if needed. 
Send copies of this report and all appendices as indicated below. 
All Grants 
Send 3 copies * 
TO: Grants Closeout Unit 
Grants Management Branch 
Office of Program Support 
National Institute of Mental Health 
5600 Fishers Lane, Room 7C-18 
Rockville, Maryland 20857 
* Send two copies only of any books included. 
These guidelines have been desi ed with relatively small 
response spaces to encourage brevity. However, do not 
restrict your response if more space is needed: be com-
plete, using additional labeled pages inserted where 
necessary (sample page included). Extensive descrip-
tions and discussions, if desired, should be made in 
addition to your summary response to the item, and 
should be placed as appendices. Discussions of issues not 
covered by these guidelines are also welcome as appen- 
dices. Use clear, concise language, avoiding highly 
technical language where practicable (this will vary for 
different types of research); appendices could be more 
technical than responses to the items. 
All publications resulting from this project, and not 
previously submitted, should be submitted with this 
report (or as soon as available); see the section on 
Dissemination. Publications should not be used in lie(f of 
responses to particular items. 
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6. 	Describe briefly the specific aims of your project, indicating major changes in direction 
from the original aims: 
The purpose of this project was to determine the feasibility of using 
primary mouse brain cell cultures as .a model system for studying the genetic 
and endocrine control of monoamine oxidase (MAO) in developing brain. To 
evaluate "feasibility," the following specific aims were proposed: 
"1. Identification and characterization of genetic variation in brain MAO. 
"Genetic variation in MAO will be identified in screening experiments of 
several inbred mouse strains. Types A- and B- MAO will be assayed in brain 
homogenates from neonatal and adult mice.... 
"Genetic variation in MAO will be characterized by determining the kinetic 
constants Km and Vmax for each form of the enzyme and by an examination of the 
rates of change in enzyme activity during early postnatal development. 
"2. Determination of the effects of hormone treatment on MAO during the 
early postnatal period. 
"The following hormones will be administered to groups of mice for the 
first 3-7 days of life: estradiol, testosterone, corticosterone, and thyroxine. 
MAO-A and -B will then be assayed in brain preparations at days 8, 15, 30, 
and 60. If genetic variation in MAO was discovered (#1, above), the hormones 
will be administered to genotypes showing the greatest differences.... 
"3. Comparison of results obtained from fresh tissue with analogous 
experiments utilizing cultured brain cells.. 
"Primary brain cell cultures will be started using the mouse genotypes 
found to show the greatest differences in vivo. MAO activity in the cultured 
cells wil be characterized in order to determine whether the genotype-
dependent variation is maintained or expressed in vitro. 
"Hormone treatments which were found to be effective in vivo will also be 





7. Were the aims pursued as originally formulated? 
	
1 [5a Yes 
2 ❑ No 
	(15) 
8. I n general, how would you characterize your research? 
(Rank any multiple answers, using "1" as most appropriate) 
TYPE OF 
RESEARCH: 
(10 El( Hypothesis development 
(17) ❑ Hypothesis testing 
(18) ❑ Development or refinement 
of methodology 
(19) ❑ Gathering of data; e.g., surveys 
(20) ❑ Other (Specify): 
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9. 	Describe the methodology used in your research, including characteristics of any sample used: 
MAO activity was assayed in homogenates prepared from fresh mouse brain 
and from brain cells which had been cultured from fetal mice for 1 to 3 weeks 
in vitro. 
All of the mice used were bred in my colony from commercially available 
strains. Adult mice were sacrificed by cervical dislocation; decapitation 
was used for fetal and neonatal mice. The gestational age of fetuses used 
for brain cell cultures was determined by recording dates of occurrence of 
vaginal plugs; daily birth records were used for determining postnatal age. 
For brain cell cultures, brains from 16-18 day fetuses were dissociated 
by trypsinization; the cells were grown in monolayer cultures in plastic 
dishes in Dulbecco's modified Eagle's medium. 
Two forms of MAO were assayed: 14c-5- hydroxytryptamine was used as the 
substrate for MAO-A; ' 14c -B-phenylethylamine was used to measure MAO-B 
activity. The assays were adapted from published methods and were validated 
for appropriate kinetics and specificity under the conditions routinely used 
in these experiments. 
10. Did you have significant technical methodological difficulties? 
(Examples: necessary measurement tools undeveloped; unexpected inadequate data base) 
If yes, describe, and explain how you dealt with them. 1 lip Yes 
2 E No 
11. 	Did you have significant practical operational difficulties? 
(Examples: trouble with equipment; loss of sample or data; difficulties with cooperating 
units) 	 Yes 
If yes, describe, and explain how you dealt with them. 	
2 50 No 
(22) 
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12. Describe (a) your conclusions or results as they relate to your specific aims (please include negative results), 
and (b) their significance in relation to the field. Avoid highly technical language where practicable. 
a.) Some genetic differences in brain MAO were found in adult mice. The largest 
RESULTS: difference was in MAO-B, where the maximum activity (Vmax) was 72% higher in 
C57BL/10 mice than in Swiss albinos (an outbred strain) and 62% higher than in 
BALBc's (an inbred strain). The Km (a measure inversely related to the affinity 
of the enzyme for substrate) was also higher in the C57BL/10 mice (by 36% and 
22%, repectively). Inbred DBA/1 mice had intermediate Km and Vmax values. 
Mixing brain homogenates from C57 and BALB mice before assay did not yield evidenc 
for enzyme activators or inhibitors in these strains. 
For MAO-A, the Vmax in DBA/1 mice was 18% higher than in Swiss mice, but 
the Km's were hardly different (7-8% higher in DBA). 
The genetic differences in MAO were found throughout postnatal development, 
but the pattern of change was different for MAO-A and -B. For type A, the 
Km showed a 30% increase between days 4 and 9 of life, with little or no change 
after that. The Vmax increased by 75% fromd days 3 to 9, and decreased after 
weaning to 67% of the highest values by adulthood. For MAO-B, the Km showed no 
change between day 3 and adulthood, but the Vmax increased 10-fold, with no 
sharp inflection point. 
When the developmental-genetic differences were studied in brain cell cultures 
strain differences in the Km and Vmax for MAO-A were maintained for .3 weeks, but 
for MAO-B in the same cultures, the differences disappeared after 1 week in vitro. 
 These results suggest that the difference in MAO-A is inherent in the brain cells, 
but the expression of the difference in MAO-B depends upon the environment in 
which the cells develop. 
Attempts to find hormonal treatments which affected the developmental 
changes in MAO in vivo and in vitro were unsuccessful. 
b.)Since some drugs which affect MAO activity are effective in treating human 
behavioral disorders, it is possible that endogenous abnormalities in MAO are 
part of the causal mechanism of the behavioral disorder. It is therefore 
important to learn how this enzyme is regulated physiologically. The work 
supported by this grant has not made a major contribution to answering this 
question, but it has demonstrated the feasibility of an in vitro approach which 
may be useful in studying various wasy by which gene activity can differentially 
affect MAO-A and -B activity. 
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R ESULTS 
(Continued) 
13. Did you have other findings not directly related to the specific aims ("serendipitous findings")? 
If yes, describe: 	 1 ❑ Yes 
(23) 
2 	No 
14. How do the overall results of your project fit into these descriptions? 
(If you had multiple expectations or hypotheses, base your response 	E Confirming your hypotheses 
on the predominant trend of the results). 	 or expectations 	 (24) 
❑ Disproving your hypotheses 
or expectations 	 (25) 
❑ Inconclusive 	 (26) 
15. Did your research result in significant methodological developments? 
If yes, describe: 
1 ❑ Yes 
(27) 
2 Ed No 
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16. How would you describe the impact of your project? 
(Rank any multiple answers, using '1" as most appropriate) 
IMPLICATIONS: 
(28) ❑ Opening up a new line of research 
(29) FE Contributing to the knowledge base 
of the field 
(30) ❑ Providing facts ready for application 
in a field 
(31) ❑ Indicative of a "dead-end" line of pursuit 
17. Do you have immediate plans for further research in this area? Yes (32) 
If yes, describe: 	 2 ❑ No 
Although I have some other things which need more "immediate" attention, 
I do plan to do further research in this area within the next year. 
The differential behavior of MAO-A and -B in brain cell cultures seems 
to be a good system in which to explore the ways the two forms of the 
enzyme are regulated. The observation that the genetic differences in MAO-A 
are maintained in culture,while those in MAO-B disappear, should lead to a 
better understanding of how gene activity in the central nervous system is 
regulated. 
18. Beyond your own plans, what is your opinion of the future directions this research area 
should take? 
In general, much.more needs to be known about the genetic and humoral 
(e.g., endocrine) regulation of brain metabolism. This enzyme system may 
be a good one to study further becuase it is clinically relevant, relatively 
easy to study, and some of the physiologically important determinants have 
been identified. 
19. Do you have specific suggestions (experiments, cautions, etc.) for other research 
in this area? 
If yes, describe: 
I 110 Yes 
2 El Nc) 
(33) 
Given the differential regulation of MAO-A and -B, it is now difficult 
to justify the assay of "MAO activity" with a non-specific substrate such 
as tryptamine, which is acted upon by both forms of the enzyme. In fact, 
some earlier work in which the sub-types were not differentially assayed, 
should probably be reevaluated. 
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IMPLICATIONS 
20. Are you aware of other researchers using your techniques, or planning to 
replicate your study, or of some individual or organization continuing 
your work? If yes, describe, and check the type of impact which best 
characterizes the impact of your research at this time. 
Yes 
2 El No (34) 
❑ Specif ic utilization 	(35) 
❑ General field impact (36) 
!Continued) 
21. As an appendix, list all publications (and articles accepted for publication) resulting from 
this project. Send any publications which have not already been submitted as appendices, 
with grant number indicated on each. 	(See instructions, page 1, regarding submission of books) 
22. Do you have any plans for future publications, papers, and/or demonstrations dealing 
with the results of this project? If so, describe briefly. Send in any future publications 
based on this project as per instructions on page one. 
One paper is In Preparation. 
DISSEMINATION: 
1 [id Yes 
2 EIN0 (") 
APPENDICES: See instructions, page 1, paragraph 3. 
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